Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
To determine the onset of action, safety and toleration of different formulations and doses
of UK-369,003 in patients with erectile dysfunction. Patients should have been previously
treated with PDE5 inhibitors and have been responders to the drugs. Duration of treatment is
4 weeks.